Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Fda crawled date : 2022 - 05 - 24 save search
Know Labs Expands Leadership Team, Adds Chief Financial Officer and Chief Product Officer, As It Gets Closer to FDA Clearance Application
Published: 2022-05-24 (Crawled : 20:00) - biospace.com/
KNWN | $2.53
|
Manufacturing
|
| O: -1.32%
H: 2.67%
C: 0.0%
VSTO | $32.36 0.59% 0.0% 500K
|
Consumer Durables
|
| O: -1.8%
H: 0.28%
C: -5.21%
fda clearance application
uniQure Announces FDA Acceptance of Biologics License Application for Etranacogene Dezaparvovec under Priority ReviewIf approved, etranacogene dezaparvovec would be the first gene therapy option for people living with hemophilia B
Published: 2022-05-24 (Crawled : 15:20) - biospace.com/
QURE | $4.68 -0.64% -0.64% 550K
|
Health Technology
|
| O: -1.35%
H: 8.88%
C: 7.74%
fda application license therapy living
FDA Accepts CSL Behring's Biologics License Application for Etranacogene Dezaparvovec for Priority Review
Published: 2022-05-24 (Crawled : 14:00) - biospace.com/
QURE | $4.68 -0.64% -0.64% 550K
|
Health Technology
|
| O: -1.35%
H: 8.88%
C: 7.74%
fda application license review
Alpine Immune Sciences Announces FDA Removes Partial Clinical Hold on NEON-2 Clinical Trial of Davoceticept (ALPN-202) in Combination with Pembrolizumab
Published: 2022-05-24 (Crawled : 13:20) - biospace.com/
ALPN | $64.535 0.16% 0.16% 4M
|
Health Technology
|
| O: 0.84%
H: 1.55%
C: -0.36%
alpn-202 fda sciences trial clinical hold
Ocugen Announces New Cell Therapy Program Following FDA Regenerative Medicine Advanced Therapy (RMAT) Recognition
Published: 2022-05-24 (Crawled : 12:00) - biospace.com/
OCGN | News A | $1.315 -0.38% -0.38% 6.5M
|
Health Technology
|
| O: -3.93%
H: 0.91%
C: -5.45%
fda program therapy rmat
MannKind’s Technosphere® Inhalation Platform Utilized in FDA-Approved Tyvaso DPI™
Published: 2022-05-24 (Crawled : 11:00) - biospace.com/
UTHR | $237.99 0.45% 0.45% 400K
|
Health Technology
|
| O: 10.26%
H: 4.52%
C: 4.01%
MNKD | $4.19 2.7% 2.63% 1.8M
|
Health Technology
|
| O: 12.33%
H: 5.25%
C: -4.53%
technosphere platform fda
FDA Approves Dermavant’s VTAMA® (tapinarof) cream, 1% for the Treatment of Plaque Psoriasis in Adults: First Topical Novel Chemical Entity Launched for Psoriasis in the U.S. in 25 Years
Published: 2022-05-24 (Crawled : 11:00) - biospace.com/
ROIV | $10.46 0.97% 0.96% 4.7M
|
Manufacturing
|
| O: 5.21%
H: 4.82%
C: 1.82%
vtama treatment fda psoriasis tapinarof plague
United Therapeutics Announces FDA Approval of Tyvaso DPI™
Published: 2022-05-24 (Crawled : 11:00) - biospace.com/
UTHR | $237.99 0.45% 0.45% 400K
|
Health Technology
|
| O: 10.26%
H: 4.52%
C: 4.01%
fda approval therapeutics
Amphastar Receives FDA Approval for Regadenoson
Published: 2022-05-24 (Crawled : 11:00) - biospace.com/
AMPH | $39.98 3.44% 3.33% 410K
|
Health Technology
|
| O: -0.98%
H: 1.84%
C: -0.96%
fda approval
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.